Physician profile
Carey M Martin
NPI 1992760714
$745,341.27
in general payments reported to CMS, 2019-2025
12 companies · $327K in 2025
The $327K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17K · 2022: $30K · 2023: $191K · 2024: $180K · 2025: $327K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $516K · Travel and Lodging: $124K · Consulting Fee: $33K · Food and Beverage: $24K · Education: $314 · Honoraria: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $516,122.00 |
| Travel and Lodging | $123,785.56 |
| Consulting Fee | $33,239.50 |
| Food and Beverage | $24,261.52 |
| Education | $314.47 |
| Honoraria | $275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $311,351.71 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $160,743.32 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $147,942.48 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $108,346.08 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Bioxcel Therapeutics, INC. | $14,073.17 | 2023-2024 | Igalmi |
| Sunovion Pharmaceuticals INC. | $2,388.60 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.33 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $125.60 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sumitomo Pharma America, INC. | $61.86 | 2023 | Latuda |
| Lundbeck LLC | $44.03 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $40.02 | 2024 | Invega Sustenna, Invega |
| Dynavax Technologies Corporation | $32.07 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carey Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.